-
Boston Marathon® Jimmy Fund Walk celebrates 35 years of inspiration and impact
Last fall, Dana-Farber Cancer Institute patients, families, and supporters joined forces to defy cancer at the 35th annual Boston Marathon® Jimmy Fund Walk presented by Hyundai, which raises the most money of any single-day walk in the nation.
-
The Hale Family receives the Sidney Farber Medical Research Award
In November 2023, Dana-Farber Trustee Judy Hale, Dana-Farber Trustee Karen Hale, Rob Hale, Elizabeth Hale Kendall, and Richard Kendall were awarded the Sidney Farber Medical Research Award in recognition of the Hale Family’s outstanding contributions and service to the Institute for many decades.
-
Jimmy Fund Golf community helps to usher in the Jimmy Fund’s 75th
Jimmy Fund Golf presented by Mohegan Sun marked another ace year in 2023, with an array of dedicated tournament directors, sponsors, and supporters across the country raising more than $6.8 million for The Dana-Farber Campaign.
-
Eliminating disparities to improve outcomes
With philanthropic support from the Scarlet Feather Fund, Dana-Farber’s Kira Bona, MD, MPH, and Christopher Lathan, MD, MS, MPH, chief clinical access and equity officer and the Hadley Family Chair at Dana-Farber, are leading bold, innovative approaches that aim to reduce disparities in outcomes for adult and pediatric cancer patients.
-
The Mark Foundation spurs innovation in immunotherapy
The Mark Foundation for Cancer Research has awarded Dana-Farber investigator Catherine Wu, MD, and two investigators at the Broad Institute a $3 million, three-year grant to further their research into personalized, T cell-directed cancer immunotherapy.
-
Investment in infrastructure accelerates immunotherapy development
The Massachusetts Life Sciences Center (MLSC) has granted Dana-Farber $2.78 million to build crucial infrastructure for developing immunotherapies—novel treatments that leverage the immune system to fight cancer.
-
V Foundation spurs pivotal research aimed at new epigenetic therapies
The V Foundation is spurring Dana-Farber Cancer Institute’s efforts to eradicate difficult-to-treat cancers through recent grants totaling $1.6 million awarded to two Dana-Farber investigators who aim to develop novel treatments known as epigenetic therapies.
-
The Paula and Rodger Riney Foundation sustains momentum in multiple myeloma research
Multiple myeloma treatments have significantly improved over the past two decades, thanks in part to the driving engine of transformational philanthropy.
-
Campbells advance research into rare ovarian cancer
Emily Campbell was just 32 when she began seeing doctors in her hometown of Miami for vague symptoms—abdominal discomfort and bloating, low appetite, fatigue—that were dismissed by her local medical team until she insisted on an ultrasound scan.
-
Edward P. Evans Foundation grants spur cutting-edge MDS research
In 2019, Dana-Farber established the Edward P. Evans Center for Myelodysplastic Syndromes (MDS) with generous funding from the Edward P. Evans Foundation. The foundation recently awarded new grants totaling $1.35 million to three Dana-Farber scientists for novel investigations into MDS, a group of blood disorders caused by abnormal bone marrow stem cells.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation.